- Researchers investigated whether platelet transfusion improves clinical outcomes for patients with sepsis associated thrombocytopenia in intensive care.
- This study analyzed 695 patients and validated results using a database of 2,739 patients with sepsis associated thrombocytopenia.
- Transfused patients had higher mortality at 53.4 percent versus 30.1 percent and longer ventilation times (p < 0.05).
- The researchers concluded that transfusions are associated with increased thrombosis risk and provide no observable clinical benefits.
- Physicians should note that 50 percent of cases demonstrated platelet transfusion refractoriness, where platelet counts fail to rise.
Reassessing the Trigger for Platelet Transfusion in Sepsis
Sepsis remains a leading cause of mortality in intensive care units, frequently complicated by sepsis-associated thrombocytopenia (a significant drop in platelet count during systemic infection) which serves as a critical marker of multi-organ dysfunction [1, 2]. While international guidelines provide robust frameworks for hemodynamic resuscitation and antimicrobial stewardship, the management of low platelet counts in these patients often relies on weak recommendations or expert opinion [3]. Clinicians frequently utilize platelet transfusions to mitigate bleeding risks, yet the physiological benefits are often offset by complications such as transfusion-related lung injury or immune modulation [1, 4]. In other vulnerable populations, such as preterm neonates, a randomized trial of 660 infants found that a higher transfusion threshold of 50,000 per cubic millimeter resulted in a significantly higher rate of death or major bleeding (26%) compared to a lower threshold of 25,000 per cubic millimeter (19%; P=0.02) [5, 6]. A multicenter retrospective analysis of 695 patients now indicates that platelet transfusions in adult septic patients are associated with increased mortality (53.4% versus 30.1%; P < 0.05) and extended intensive care unit stays, challenging the routine use of this intervention to correct laboratory abnormalities [7].
Increased Mortality and Resource Utilization in Transfused Patients
The researchers investigated the effects of platelet transfusion on sepsis-associated thrombocytopenia, a condition characterized by a rapid decline in platelet counts during systemic infection that complicates clinical management. The discovery cohort included 695 patients admitted to Peking Union Medical College Hospital from June 8, 2013, to October 12, 2022. To ensure the reliability of the findings, external validation was performed using a larger cohort of 2,739 patients from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. In both cohorts, patients were divided into two groups based on whether they received a platelet transfusion during their hospital stay.
To minimize the impact of confounding variables, the authors utilized propensity score-matching (a statistical method used to reduce selection bias by equating groups based on baseline clinical characteristics, ensuring a fair comparison). After this matching process, the study found that mortality was significantly higher in the platelet transfusion group at 53.4% compared to 30.1% in the control group (P < 0.05). Clinical outcomes related to respiratory support and intensive care were also negatively affected, raising concerns about the physiological burden of transfusions. The platelet transfusion group required a mechanical ventilation time of 169 hours, whereas the control group averaged 43 hours (P < 0.05). Furthermore, intensive care unit stays were significantly longer for transfused patients, totaling 227 hours compared to 133 hours in the control group (P < 0.05).
The increased clinical complexity in transfused patients translated to longer hospitalizations and higher costs. Total hospital stays reached 817 hours in the transfusion group compared to 536 hours in the control group (P < 0.05). When analyzing the duration of care specifically after the diagnosis of sepsis-associated thrombocytopenia, hospital stays remained longer for those receiving transfusions at 636 hours versus 384 hours for those who did not (P < 0.05). These extended stays contributed to a near doubling of total medical expenses, which rose to 254.03 thousand yuan in the transfusion group compared to 122.29 thousand yuan in the control group (P < 0.05). Subgroup analysis based on the degree of thrombocytopenia and the data from the MIMIC-IV database confirmed these primary results, suggesting a consistent association between platelet administration and poorer clinical outcomes in septic patients. For practicing intensivists, these data suggest that reflexive transfusion protocols may inadvertently prolong critical illness rather than resolve it.
High Rates of Refractoriness and Thrombotic Risk
A critical finding of the study was the low clinical efficacy of platelet administration in the context of sepsis. The effective platelet transfusion rate, defined as the percentage of patients achieving the desired increase in platelet count following administration, was only 52.51%. This indicates that approximately 50% of platelet transfusions in sepsis-associated thrombocytopenia were characterized as platelet transfusion refractoriness (a clinical state where the patient fails to achieve the expected post-transfusion increase in platelet levels, often due to rapid consumption or immune destruction). Contrary to clinical intuition, the researchers observed that as the baseline platelet count decreased, the effective platelet transfusion rate also tended to decrease. This suggests that the most severely thrombocytopenic patients, who are typically the primary targets for intervention, may actually be the least likely to benefit from supplementation.
The administration of platelets was also associated with an increased risk of venous thromboembolism, complicating the clinical picture for physicians trying to balance bleeding and clotting risks. While the overall positive rate of deep vein thrombosis in the Peking Union Medical College Hospital cohort was 18.85%, this risk was significantly higher among specific subgroups receiving transfusions. In patients with a moderate platelet count between 50 and 100 × 10^9/L, those in the transfusion group experienced a higher rate of deep vein thrombosis (33 out of 92 patients) compared to the control group (27 out of 131 patients), a result that reached statistical significance (P < 0.05). These data suggest that in the setting of sepsis, platelet transfusions frequently fail to achieve their intended physiological effect while simultaneously increasing the risk of thrombotic complications. For clinicians managing septic patients, these findings highlight the need to carefully weigh the theoretical benefits of correcting a laboratory value against the tangible risks of thrombosis and transfusion refractoriness.
References
1. Wu Q, Ren J, Wang G, et al. Evaluating the safety and efficacy of recombinant human thrombopoietin among severe sepsis patients with thrombocytopenia: study protocol for a randomized controlled trial.. Trials. 2015. doi:10.1186/s13063-015-0746-6
2. Zhou Z, Feng T, Xie Y, et al. The effect of recombinant human thrombopoietin (rhTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial). BMC Infectious Diseases. 2019. doi:10.1186/s12879-019-4388-2
3. Rhodes A, Evans L, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Critical Care Medicine. 2017. doi:10.1097/ccm.0000000000002255
4. Zhang J, Lu Z, Xiao W, Hua T, Zheng Y, Yang M. Efficacy and Safety of Recombinant Human Thrombopoietin on Sepsis Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2020. doi:10.3389/fphar.2020.00940
5. Curley A, Stanworth S, Willoughby KA, et al. Randomized Trial of Platelet-Transfusion Thresholds in Neonates. New England Journal of Medicine. 2018. doi:10.1056/nejmoa1807320
6. Ribeiro H, Assunção A, Vieira R, Soares P, Guimarães H, Flôr-de-Lima F. Platelet transfusions in preterm infants: current concepts and controversies—a systematic review and meta-analysis. European Journal of Pediatrics. 2023. doi:10.1007/s00431-023-05031-y
7. Wang L, Pan W, Du B, Zhou X. Effects of Platelet Transfusion on Sepsis Associated Thrombocytopenia (SAT): A Multicenter Retrospective Chart Review.. Journal of intensive care medicine. 2026. doi:10.1177/08850666261448808